2-Methyl-1-[3-(2-methylpropanoyl)phenyl]propan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methyl-1-[3-(2-methylpropanoyl)phenyl]propan-1-one
• 化学式: C₁₄H₁₈O₂
• 分子量: 218.29
• InChiKey: IKZJHJTVXNPDPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS
  申请人：Bracco Imaging S.p.A

  公开号：EP2149568A1

  公开（公告）日：2010-02-03

  The invention relates to dimeric aryl-sulphonamido compounds endowed with inhibitory activity against metalloproteases MMP, having formula (I) below          (M)-L-(M')     (I) wherein M and M', the same or different from each other, represent the residues of the mctalloprotcascs inhibitors of formula (II) wherein R, R1, R2, R3, G and n have the meanings reported in the specification; the invention also refers to the process for their preparation, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly in the treatment of degenerative disorders.

  该发明涉及具有对金属蛋白酶MMP具有抑制活性的二聚芳基磺胺基化合物，其具有以下式(I)：(M)-L-(M')，其中M和M'，相同或不同，代表具有以下式(II)金属蛋白酶抑制剂的残基，其中R、R1、R2、R3、G和n在说明书中有所述；该发明还涉及其制备方法，包括它们的药物组合物以及它们作为治疗剂的用途，特别是在治疗退行性疾病方面。
• Potent non-urea inhibitors of soluble epoxide hydrolase
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US10005732B2

  公开（公告）日：2018-06-26

  The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.

  本发明涉及通过抑制可溶性环氧化物水解酶（sEH）的活性而表现出扩张血管和抗炎作用的化合物。本发明还涉及鉴定此类化合物的方法，以及使用此类化合物治疗与血管扩张、炎症和/或内皮细胞功能障碍有关的疾病。在特别的非限制性实施方案中，本发明的成分可用于治疗高血压。
• Insulin receptor partial agonists and GLP-1 analogues
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10953076B2

  公开（公告）日：2021-03-23

  The present invention provides compositions comprising insulin receptor partial agonists in association with GLP-1 analogues (e.g., liraglutide) as well as methods for using the compositions for example, to treat or prevent diabetes or to decrease body weight.

  本发明提供了包含胰岛素受体部分激动剂与 GLP-1 类似物（如利拉鲁肽）的组合物，以及使用这些组合物治疗或预防糖尿病或减轻体重的方法。
• POLYARYLETHER KETONE IMIDE SULFONE ADHESIVES
  申请人：The Boeing Company

  公开号：EP3216820B1

  公开（公告）日：2020-09-23
• IAP BIR DOMAIN BINDING COMPOUNDS
  申请人：Laurent Alain

  公开号：US20100203012A1

  公开（公告）日：2010-08-12

  Disclosed herein is a compound of Formula 1: or a salt thereof, in which R 1 , R 1a , R 100 , R 100a , R 2 , R 200 , R 3 , R 300 , A, A 1 , Q, Q 1 and BG are as defined herein. Also disclosed is the use of the compounds of Formula 1 to treat disorders of dysregulated apoptosis, such as cancer and cellular proliferative disorders.